Expert panel recommends SGLT2 inhibitor or GLP-1 receptor agonist for patients with type 2 diabetes and CVD | ACP Internist Weekly | ACP Internist
The American College of Cardiology's new decision pathway also calls for repeated HbA1c screening and detailed clinician-patient risk discussions for patients with cardiovascular disease (CVD) who are diagnosed with type 2 diabetes.
ACP Internist provides news and information for internal medicine physicians about the practice of medicine and reports on the policies, products, and activities of ACP.
Managing kidney disease in diabetes requires meeting individualized parameters and balancing risks in nephrology and cardiology. Learn whether more aggressive treatment is warranted in this population.
As doctors, sometimes the biggest lessons that we learn about disease pathology are those that we learn from the people that have that disea...
The latest news, ideas and trends in internal medicine.
To improve metrics of diabetes care, 4 employed primary care practices at a health system in Texas worked to systematically improve HbA1c testing and started a “Saving Toes” campaign.
This column reviews a warning on fluoroquinolones with a risk of disabling and potentially permanent side effects, as well as approval of an injection to improve glycemic control in adults with type 2 diabetes.
The onus is on internists to understand the newer classes of incretins such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. They hold promise for better treatments, but they are new and not as well
Learn 10 guiding principles for the care of people with or at risk for diabetes.
Just as diabetes is affecting younger populations, so are its consequences. Childhood obesity can translate into diabetic retinopathy in patients in their 20s, which requires a response from the primary care community.